An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O’Connor will present at the BofA Securities 2021 Tech Solutions for Drug Discovery Conference on September 20, 2021, at 10:00 a.m. ET, and at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 22, 2021, at 9:55 a.m. ET. One-on-one meetings will also be held at both events. Live webcasts and presentations will be accessible via the Investors page of the Simulations Plus website for 90 days.
Positive
None.
Negative
None.
LANCASTER, Calif.--(BUSINESS WIRE)--
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at two upcoming investor conferences:
BofA Securities 2021 Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021. The Company’s presentation will begin at 10:00 a.m. ET.
The Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 22, 2021. The Company’s presentation will begin at 9:55 a.m. ET.
Mr. O’Connor will host one-on-one meetings throughout the day at both events. Live webcasts of the Company’s presentations, along with the accompanying slide presentations, will be available on the Investors page of the Simulations Plus website; the webcast replays will be available for 90 days. For more information about the conferences or to schedule a one-on-one meeting with Simulations Plus, please contact Hayden IR at slp@haydenir.com.
About Simulations Plus, Inc.
Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries Cognigen, DILIsym Services, and Lixoft, we offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report.
When is Simulations Plus scheduled to present at the BofA Securities conference?
Simulations Plus will present at the BofA Securities 2021 Tech Solutions for Drug Discovery Conference on September 20, 2021, starting at 10:00 a.m. ET.
What date is the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit?
The Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit is on September 22, 2021, with a presentation at 9:55 a.m. ET.
Will the presentations from Simulations Plus be available online?
Yes, live webcasts of the presentations will be available on the Simulations Plus Investors page and will remain accessible for 90 days.
How can I contact Simulations Plus for a one-on-one meeting?
You can schedule a one-on-one meeting with Simulations Plus through Hayden IR via email at slp@haydenir.com.
What does Simulations Plus specialize in?
Simulations Plus specializes in modeling and simulation software and services for pharmaceutical safety and efficacy.
